€44.6m market cap
€0.98 last close
Pixium Vision develops bionic vision systems for patients with severe vision loss. Its lead product, Prima, is a wireless sub-retinal implant system designed for dry-AMD. The company recently started a European pivotal study.
Investment summary
Pixium Vision is developing the Prima wireless photovoltaic sub-retinal implant, which transforms images into electrical signals to elicit a form of central visual perception in patients with severe retinal disease. Positive 18-month data from its EU feasibility study in patients with geographic atrophy associated with dry age-related macular degeneration (GA-AMD) showed improvements of between three and seven lines on the Landolt C visual acuity scale versus baseline. Pixium recently started the PRIMAvera pivotal study in Europe, which we believe could lead to potential CE Mark and EU market launch in H223.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 1.6 | (5.8) | (7.7) | (41.63) | N/A | N/A |
| 2019A | 1.8 | (8.4) | (9.8) | (43.90) | N/A | N/A |
| 2020E | 1.7 | (7.4) | (8.6) | (27.76) | N/A | N/A |
| 2021E | 1.6 | (9.4) | (11.0) | (25.38) | N/A | N/A |
Industry outlook
Pixium in January entered a memorandum of understanding to combine its business with Second Sight, which is developing the Orion Visual Cortical Prosthesis System. The stock-based transaction, planned to close in Q221, will enable both companies to pool their resources in complementary sight-restoration neuromodulation technologies and may also broaden access to future financing.
Last updated on 26/02/2021
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (€m) | 3 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Lloyd Diamond | CEO |
| Guillaume Renondin | CFO |
You may also be interested in…
- 4SC
- Abliva
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- Allarity Therapeutics
- ASIT biotech
- Basilea Pharmaceutica
- BerGenBio
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- Newron Pharmaceuticals
- Nicox
- Nuevolution
- Oasmia Pharmaceutical
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Polyphor
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma